Bull & Bear

Bull and Bear

Verdict: Avoid — the Q4 FY2025 print already ran the operating-leverage experiment the bull case rests on, and it failed (4.2% gross margin on $26.2M of revenue), while the stock still trades at 29.2x EV/Sales with an active securities class action, a disclosed material weakness, and three CFOs in twelve months. The bull is right that RCAT holds a real Program of Record inside an NDAA-walled demand pool with $167.9M of cash; that's why this is "Avoid," not "Lean Short." But the decisive tension — whether scaling Black Widow lifts unit economics — is the one tension already partially decided against the bulls, and the credibility file is too dirty to extend the benefit of the doubt on forward claims that haven't yet hit the P&L. The verdict flips back to "Watchlist" if Q1/Q2 FY26 prints two consecutive quarters of >15% gross margin on $30M+ of quarterly revenue.

Bull Case

Target and trigger. Bull's price target is $22 (12-18 months) on 9x FY27E EV/Revenue against a $250M revenue base, cross-checked to the $21 analyst median. Primary catalyst is the SRR Tranche 2 / full-rate production award, expected calendar Q3-Q4 2026. Disconfirming signal: Q2 FY26 gross margin printing below 10% on a $30M+ revenue quarter — that single observation refutes the operating-leverage premise the entire case rests on.

Bear Case

Downside and trigger. Bear's downside target is $5.00 (12-18 months, ~53% below the May 7, 2026 close of $10.62), via peer-multiple compression to 5x EV/Sales on bear-case FY26 revenue of $100M plus 10-15% additional dilution. Cover signal: two consecutive quarters of gross margin above 15% on >$30M of quarterly revenue and sole-source confirmation on SRR Tranche 3 — either alone is insufficient.

The Real Debate

Verdict

Verdict: Avoid. The bear case carries more weight because the single most decisive tension — whether scaling Black Widow lifts unit economics — has already been partially adjudicated by the Q4 FY2025 print, and the answer was 4.2% gross margin on $26.2M of revenue, with incremental gross margin of roughly 3% on a 2.7x revenue step-up. That is the controlled experiment the bull thesis explicitly invited, and it is layered on a securities class action, a disclosed material weakness in ICOFR, three CFOs in twelve months, $22M of insider selling against zero buying, and a 29.2x EV/Sales multiple that prices AVAV-tier economics already. The bull could still be right: the NDAA / FCC / ASDA regulatory wall is real, the Program of Record is real, the $167.9M cash position genuinely funds the ramp, and one quarter of overhead absorption math is not a five-year fact pattern. The verdict flips to "Watchlist" if RCAT prints two consecutive quarters of gross margin above 15% on >$30M of quarterly revenue with no further guide-downs and no SEC formal inquiry on the SRR-value or SLC-capacity disclosures — short of that, the burden-of-proof is wrong-way around for the multiple being asked.